Home > Boards > US Listed > Biotechs > Affimed Therapeutics (AFMD)

I know most people don't do their due

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
BobDoleYahoo Member Profile
 
Followed By 52
Posts 784
Boards Moderated 0
Alias Born 07/11/17
160x600 placeholder
Affimed Reports Progress on Key Clinical Development Programs GlobeNewswire Inc. - 10/15/2019 6:30:00 AM
Affimed to Participate in Investor Conferences in September GlobeNewswire Inc. - 8/28/2019 5:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/7/2019 8:24:54 AM
Affimed Reports Second Quarter 2019 Financial and Operational Results GlobeNewswire Inc. - 8/7/2019 7:30:00 AM
Affimed Announces Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 7, 2019 GlobeNewswire Inc. - 7/31/2019 5:00:00 AM
Affimed Added to the Russell 2000®, 3000® and Microcap Indexes GlobeNewswire Inc. - 7/1/2019 5:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/27/2019 4:20:20 PM
Affimed Announces Clinical Data Update on Lead Product Candidate AFM13 in CD30+ lymphoma at ICML 2019 GlobeNewswire Inc. - 6/24/2019 5:00:00 AM
Affimed to Present Data on AFM13 at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland GlobeNewswire Inc. - 6/12/2019 5:30:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/4/2019 4:18:14 PM
Affimed Announces Annual General Meeting of Shareholders GlobeNewswire Inc. - 6/4/2019 4:01:00 PM
Icosagen and AbCheck Announce Five-year Licensing Agreement Granting AbCheck Access to Icosagen’s Patented Mammalian Expres... GlobeNewswire Inc. - 6/3/2019 5:00:00 AM
Affimed to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire Inc. - 5/29/2019 5:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/22/2019 7:38:59 AM
Affimed Announces R&D Strategy to Focus on Innate Immunity Portfolio; Reports First Quarter 2019 Financial Results and Operat... GlobeNewswire Inc. - 5/22/2019 7:30:00 AM
Affimed Announces First Quarter 2019 Financial Results and Corporate Update Conference Call on May 22, 2019 GlobeNewswire Inc. - 5/16/2019 5:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 4/17/2019 4:12:05 PM
Affimed Provides Regulatory Update on AFM11 Clinical Program GlobeNewswire Inc. - 4/17/2019 4:05:00 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 4/11/2019 4:36:18 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 4/9/2019 7:49:11 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 4/5/2019 4:10:39 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 4/2/2019 9:20:33 AM
Affimed Highlights AFM24 Innate Cell Engager Novel Mechanism of Action and Potential for the Treatment of EGFR-expressing Sol... GlobeNewswire Inc. - 4/1/2019 8:00:00 AM
Affimed Reports 2018 Financial Results and Operational Progress GlobeNewswire Inc. - 3/27/2019 7:30:00 AM
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 3/27/2019 7:03:50 AM
BobDoleYahoo   Thursday, 08/30/18 04:54:23 AM
Re: None
Post # of 88 
I know most people don't do their due diligence or read SEC filings, so I have done it for you. Let's compare $FATE to $AFMD

Pipelines are similar, in pre-clinical and phase 1:

$AFMD's pipeline: http://www.affimed.com/products.php
$FATE's pipeline: http://fatetherapeutics.com/pipeline/

$FATE's market cap: $664.53 million
$AFMD's market cap: 383.7 million

$FATE's cash on hand: $78.02 million
$AFMD's cash on hand: $55.23 million

$FATE's debt: $14.85 million
$AFMD's debt: $6.93 million

$FATE's last 10-Q states they think they'll have sufficient cash for next 12 months.
$AFMD's last 6-K quarterly report states they'll have sufficient cast through Q4, 2019 (the $96 million spread over a year, will most likely extend that duration out)

If $AFMD were to trade at $664 million market cap, that works out to be: $664.53 / 62.39 million shares = $10.65. However, the fact that Genentech is willing to foot most of the bill for the R&D costs AND they are receiving the $96 million over the period of a year, this should bring up the value significantly.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist